T cell proliferation and the calculation of a stimulation index are one of the mostly widely used methods in both mouse and man to demonstrate antigen specific immunity. We propose to define a """"""""second generation"""""""" assay to replace traditional lymphocyte proliferation assays using [3H]thymidine uptake. Multiparameter flow cytometry will be used to assess antigen-specific T cell proliferation by measuring incorporation of BrdU, a thymidine analog. In addition to proliferating T cells, surface markers associated with proliferating cells will be examined. Surface markers to be examined will include CO27, CD45RO/RA, and CO95. These are all markers that can be used, singly or in combination, to distinguish naive from memory cells. Antigen-specific BrdU incorporation will be used to identify proliferating antigen-responsive cells, so that analysis of other markers can be perfoffi1ed by gating on these cells. In a preliminary study using SEB as a stimulus, positive correlation was observed between flow cytometric measurement of proliferating CD4+ T cells by BrdU incorporation and a standard proliferation assay measuring [3H]thymidine uptake by PBMC. We propose to extend the use of BrdU proliferation assay using flow cytometry in assessing T cell proliferative responses to CMV, flu, and tumor antigens.
The aim of this pilot project will be to correlate lymphocyte proliferation assay using non-radioactive BrdU incorporation measured by multiparametric flow cytometry and a standard radioactive [3H]thymidine incorporation assay in the following systems: CMV, influenza, and at least one of the candidate cancer antigens to be evaluated by the consortium (MAGE-3, HER2, CEA, or gp100).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA090818-01
Application #
6485121
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-07-30
Project End
2006-12-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Slota, Meredith; Lim, Jong-Baeck; Dang, Yushe et al. (2011) ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 10:299-306
Coveler, Andrew L; Goodell, Vivian; Webster, Devon J et al. (2009) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 113:95-100
Maecker, Holden T (2009) Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 485:375-91
Ladd, Jon; Lu, Hailing; Taylor, Allen D et al. (2009) Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 70:1-6
Maecker, Holden T; Hassler, Jeffrey; Payne, Janice K et al. (2008) Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9:9
Goodell, Vivian; Waisman, James; Salazar, Lupe G et al. (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449-54
Park, Kyong Hwa; Gad, Ekram; Goodell, Vivian et al. (2008) Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68:8400-9
Goodell, Vivian; McNeel, Douglas; Disis, Mary L (2008) His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 9:23
Siebert, Janet C; Inokuma, Margaret; Waid, Dan M et al. (2008) An analytical workflow for investigating cytokine profiles. Cytometry A 73:289-98
Goodell, Vivian; dela Rosa, Corazon; Slota, Meredith et al. (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 8:21

Showing the most recent 10 out of 23 publications